What s the difference? Challenges in pre-clinical development of biologics
|
|
- Roger Wilkerson
- 6 years ago
- Views:
Transcription
1 Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31 March 2011 Acknowledgements: Jennifer Sims, Phil Lowe, Sebastian Spindeldreher, Andrew Warren
2 Protein therapeutics biologics Current generation recombinant proteins, binding proteins, cytokines; pegylated proteins: antibodies (mabs), antibody fragments (e.g. Fabs), antibody drug conjugates (ADCs) Next generation? above proteins with non-natural amino-acids / post-translational modifications (eg altered glycosylation pattern), nanobodies, bi-specific antibodies, new scaffolds Slide 2 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
3 Monoclonal antibodies vs NCEs: mab New Chemical Entity 150,000 dalton dalton Biological production process heterogeneous (post-translational modifications) High species selectivity (affinity / potency) Multi-functional target binding, Fc effector function, FcRn binding Toxicity largely on target mediated exaggerated pharmacology Slow clearance; long half-life (days) infrequent dosing (weekly / monthly)? Target can affect PK behaviour (Target Mediated Drug Disposition) Drug-Drug Interaction few examples and mostly PD related Immunogenicity sometimes observed Chemical production process - homogeneous Generally less selective Single target Toxicity often off target mediated Rapid clearance; short half-life (hours) frequent dosing (daily) Mostly linear PK; non-linearity from saturation of metabolic pathways DDI many examples and metabolic and/or PD related Immunogenicity rarely observed Slide 3 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
4 Outline of the presentation: PK-PD behaviour of mabs - inherent IgG characteristics - binding models and Target Mediated Drug Disposition Developing an integrated bio-analytical strategy - PharmacoKinetics - PharmacoDynamics (target ) - Immunogenicity Selection of appropriate starting doses for early clinical testing - FDA guidance NOAEL / (PAD) MABEL Summary Slide 4 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
5 A simple mab PK model mab iv dose elimination mab limited volume of distribution ~ 7L slow clearance t ½ ~ 20 days (human) FcRn (tight binding at ph6) protects IgG from degradation & explains long serum half-life Roopenian and Akilesh. Nature Reviews Immunology 2007; 7: 715 Slide 5 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
6 Mouse, rat and monkey FcRn recognise human IgG NB - binding affinity of human IgG to mouse FcRn is 10x higher than to human FcRn rat cynomolgus monkey mouse - inherent human IgG kinetics scales reasonably well across species - NB when target mediated disposition is absent Slide 6 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
7 lower FcRn binding affinity Engineered proteins may have altered FcRn binding fusion proteins chimeric mabs human mabs - cept - iximab - umab shorter half-life Suzuki T et al: Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR J Immunol 2010; 184: Slide 7 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
8 Ligand binding model (closed system) mab + mab complex at equilibrium: K d = [mab]. [] [mab- complex] Assumptions: - static system; no turnover of, no loss of mab to distribution and elimination, instantaneous equilibrium Slide 8 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
9 Ligand binding model (closed system) TGN1412 mab + mab complex K d = 1.88 nm dose 0.1 mg/kg MW 150,000 plasma volume 2.5L TGN1412 = 18.7 nm (immediately post-dose) Tcell 1.9 x 10 6 ml -1 CD28 / cell 150,000 CD28 = 0.95 nm at baseline Receptor occupancy (%) Dose (mg/kg) Assumptions: - static system; no turnover of, no loss of mab to distribution and elimination, instantaneous equilibrium Slide 9 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March
10 A simple mab PK-PD model input mab + mab complex dose elimination mab slow clearance elimination rapid clearance Soluble target: mab- complex tends to take on the elimination characteristics of the mab elimination mab complex Cellular target: mab- complex tends to take on the elimination characteristics of the (TMDD apparent) Slide 10 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
11 Typical mab PK-PD model(s) Lowe PJ et al: On setting the first dose in man: Quantitating biotherapeutic drugtarget binding through PK and PD models Basic & Clin Pharmacology & Toxicology 2009; 106: Slide 11 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
12 Example 1: mab against cell surface anti-cd11a mab Raptiva (efalizumab) - rapid clearance of mab-receptor complex - high doses saturate target binding capacity with a return to normal IgG kinetics mab complex increasing dose: change in IgG kinetics (TMDD) Target Mediated Drug Disposition increasing dose: increases duration of effect Joshi et al An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis J Clin Pharmacol 2006; 46: Slide 12 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
13 Concentration (linear scale) nm Concentration (log scale) nm Example 2: mab against soluble (MCP-1) mab complex - slow elimination of mab- complex - accumulation of total - rapid turnover of - rapid saturation of binding capacity - long half-life total mab short duration of effect Accumulation inactive complex 1 x 0.1 mg/kg 2 x 0.3 mg/kg total total mab total mab free (not measured) total free mab (not measured) Time (days) Time (days) Slide 13 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
14 Example 3: mab against soluble (IL1-b) - slow elimination of mab- complex - saturable accumulation of total mab complex - long half-life total mab; long duration of effect Accumulation inactive complex Measured ACZ885 (2 x 10mg/kg) Measured total IL-1β Slide 14 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
15 Example 3: mab against soluble (IL1-b) mab complex Accumulation inactive complex Measured total ACZ885 increasing dose: no change in IgG kinetics Simulated free IL1-b increasing dose: increases duration of effect 10 mg/kg 3 mg/kg 1 mg/kg 0.3 mg/kg 0.1 mg/kg 0.1 mg/kg 0.3 mg/kg 1 mg/kg 3 mg/kg 10 mg/kg Slide 15 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
16 Scalable components of the PK-PD model: Inherent pharmacokinetics of the mab and clearance of the mab- complex: - PK of monoclonal antibodies will generally follow typical IgG behaviour and scale reasonably well to man and/or exhibit Target Mediated Disposition and be dependent on the amount of target present and its rate of turnover Binding affinity and potency against the target : - species differences understood during characterisation of the mab Expression and turnover of the : - key drivers of the extent and duration of response; can affect PK behaviour - once maximum binding is achieved then increasing the dose will primarily increase the duration of response: are SAD/MAD designs appropriate for early clinical development? - species differences and differences between healthy individuals vs disease often not well understood Slide 16 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
17 Outline of the presentation: PK-PD behaviour of mabs - inherent IgG characteristics - binding models and Target Mediated Drug Disposition Developing an integrated bio-analytical strategy - PharmacoKinetics - PharmacoDynamics (target ) - Immunogenicity Selection of appropriate starting doses for early clinical testing - FDA guidance NOAEL / (PAD) MABEL Summary Slide 17 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
18 Bioanalytical strategy - PK Free- bioactive mab Total mab sandwich ELISA anti-human IgG mab (drug) anti-human IgG mab (drug) anti-human IgG sandwich ELISA (pre-clinical only) mab (drug) competitive ELISA protein digestion bridging ELISA mab (drug) protein LCMS unique signature peptide Slide 18 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
19 Bioanalytical strategy PD (soluble ) total (target capture) anti Ab2 mab (drug) anti Ab1 + + sandwich ELISA endogenous binding protein free anti Ab4 anti Ab3 sandwich ELISA mab (drug) endogenous binding protein Technically challenging: detection of total (increasing) in the presence of drug and endogenous binding protein (if relevant) careful selection of capture and detection reagents (Ab1 and Ab3 Technically very challenging: detection of free (decreasing) in the presence of increasing concentrations of total specificity and sensitivity (LLOQ) Slide 19 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
20 Bioanalytical strategy - immunogenicity Biacore Bridging ELISA mab (drug) labelled ADA ADA mab (drug) mab (drug) non-neutralising neutralising non-neutralising neutralising Consequences of immunogenicity: - increase in clearance of mab (immune complexes) - decrease in capacity for target binding (neutralising immunogenicity) - influence on PK and/or PD assays integrated assessment? Slide 20 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
21 anti-human interleukin mab [µg/ml] Serum concentration rel. Response Unit [RU] Example 4: mab against cell surface (receptor) Single dose 10 mg/kg i.v. n=3 animals 300 PK profile Immunogenicity Time [day] competitive ELISA mab (drug) Time [day] Biacore ADA mab (drug) Slide 21 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
22 Serum concentration [ug/ml] Rel Response Untis [RU] Example 4: mab against cell surface (receptor) Three doses 100 mg/kg i.v. days 0, 7, 14 (n=3 animals) PK assay mab (drug) bridging ELISA Immunogenicity ADA Days - bridging ELISA overcomes limitations of competitive ELISA to measure exposure to drug in presence of ADA response - rapid clearance of drug due to nabs and/or rapid clearance of immune complexes Slide 22 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011 Biacore mab (drug)
23 Outline of the presentation: PK-PD behaviour of mabs - inherent IgG characteristics - binding models and Target Mediated Drug Disposition Developing an integrated bio-analytical strategy - Pharmacokinetics - Pharmacodynamics (target ) - Immunogenicity Selection of appropriate starting doses for early clinical testing - FDA guidance NOAEL / (PAD) MABEL Summary Slide 23 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
24 FDA guidance: 2005 Step 1 Determine No Observable Adverse Effect Level (NOAEL) Step 2 Step 3 Convert NOAEL to a Human Equivalent Dose (HED) - generally normalised to body surface area (low MW NCEs) - mg/kg normalisation recommended for proteins >100K daltons Select HED from the most appropriate species - additional factors: metabolism, receptors, binding epitopes - default: most sensitive species (lowest HED) Step 4 Apply a safety factor (>10-fold) to give a: Maximum Recommended Starting Dose (MRSD) Step 5 Adjust MRSD based on the pharmacologically active dose (PAD) Slide 24 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
25 FDA guidance: 2005 Pro simple to use supported by historical evidence (mainly conventional NCEs) Con implicit in guideline primary focus: NOAEL (steps 1-4) secondary focus: pharmacologically active dose (PAD) over simplified scaling to man focus on dose not exposure one algorithm fits all step 5 often ignored Slide 25 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
26 NOAEL and MABEL (PAD) NOAEL No Observable Adverse Effect Level FDA highest dose level that does not produce a significant increase in adverse effects an effect that would be unacceptable if produced by the initial dose of a therapeutic in a phase I clinical trial conducted in adult healthy volunteers MABEL - Minimal Anticipated (Acceptable) Biological Effect Level minimal exposure / dose level that is anticipated to produce an acceptable biological effect an effect that would be considered acceptable if produced by the initial dose of a therapeutic in a phase I clinical trial Slide 26 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
27 NOAEL and MABEL MABEL NOAEL Mueller et al The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies Current Opinion in Biotechnology 2009; 20(6): Slide 27 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
28 Example 5: target suppression in safety assessment mab complex humanised mab; high affinity against soluble target Accumulation inactive complex K d man < cynomolgus monkey (~10-fold) typical IgG kinetics target can be measured in the systemic circulation at baseline and is increased in disease mab acts as a capture system : mab- complex (detected in serum) is a biomarker for suppression of free via a PK/PD model previous experience with a similar molecule (lower affinity) against the same target Slide 28 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
29 Concentration (µg/ml) Concentration (µg/ml) (ng/ml) Concentration Concentration (µg/ml) Concentration (ng/ml) Example 5: 4wk GLP toxicology study mab complex 100 Accumulation inactive complex 10 PK-PD model: exposure and 100 total PK (exposure) DOSE: 0 DOSE: DOSE: 0 DOSE: DOSE: DOSE: 10 DOSE: DOSE: pre-clin exposure data conform to a 2-compartment model DOSE: DOSE: DOSE: Time (days) Time (days increase in total (measured) fitted to binding model PK-PD model allows estimation of free (target 0 suppression) Time (days) Time (days) NB: free (green) not measured Time (days) PD (total ) Slide 29 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
30 Serum concentration (ug/ml) Example 5: predicted exposure (PK) in man mab complex 0 Accumulation inactive complex Cynomolgus monkey PK-PD model scaled to human: Cynomolgus monkey 120mg/kg NOAEL (observed mean data) >100-fold exposure safety margin (C max ) - IgG PK behaviour mg/kg - increased target binding affinity (10-fold) mg/kg 0.3 mg/kg 1.0 mg/kg 3.0 mg/kg Time (days) Slide 30 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
31 Concentration (ng/ml) Concentration (ng/ml) Example 5: predicted PD (effect) in man mab complex Simulation: predicted target suppression in man - pre-clin exposure data adjusted to man - binding affinity in PK-PD model adjusted to man Accumulation inactive complex MABEL predicted free mg/kg 0.3 mg/kg Monte-Carlo simulation mg/kg 3 mg/kg 10 mg/kg Time (days) Time (days) Slide 31 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
32 Example 5: Justification of starting dose in man Toxicology (exposure) [1] NOAEL 120 mg/kg [2/3] HED 120 mg/kg - adjust for anticipated exposure in man? [4] Apply >10-fold safety factor 12 mg/kg Pharmacology (response) [5] PAD / MABEL - justify based on pharmacology - max pharmacology achieved at 20mg/kg (6-fold lower than NOAEL) - adjust for anticipated exposure in man (0.1 mg/kg projected to give >100-fold margin) - include anticipated duration of effect - adjust for inter-species differences in affinity / potency (>50% suppression for <48h) 0.1 mg/kg Maximum Recommended Starting Dose - define anticipated safety window based on NOAEL and MABEL * 0.1 mg/kg * - NB an additional factor may be added based on uncertainty of data / prediction and relative risk Slide 32 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
33 Benefits of an Integrated Approach Simple mathematical representation of known biology also represents components of the model which cannot be measured (e.g. low circulating level of free ) Hypothesis testing the ability to test assumptions prior to experimental design, leading to better pre-clinical and clinical studies Sensitivity analysis elements of the model which are key drivers of the desired outcome (e.g. target expression / target turnover / affinity / potency) Slide 33 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
34 Summary: Challenges in pre-clinical development of biologics Inherent IgG characteristics make mabs attractive drug targets; however; unlike small MW new chemical entities (NCEs): target biology can affect PK behaviour of mabs / duration of action - target expression (how much and where?) and target turnover (how quickly is it replaced?) - normal vs disease, gender, species differences should be understood - other sinks (e.g. shed or decoy receptors), off target binding, endogenous binding proteins A bioanalytical strategy and appropriate tools needs to be developed - integrated interpretation of PK, target binding and immunogenicity An integrated PK/PD-(IG) approach can quickly identify appropriate dose and dosage regimen to achieve desired target suppression - influence and impact on traditional study design Slide 34 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011
35 Slide 35 Early Pre-Clin Dev of Biologics Peter Lloyd Berlin March 2011 Thank you for your attention
Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations. [mabs -monoclonal antibodies ] Peter Lloyd
Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations [mabs -monoclonal antibodies ] Peter Lloyd Head of Pharmacokinetics-Pharmacodynamics Novartis Biologics
More informationCHALLENGES AND SOLUTIONS TO RECEPTOR OCCUPANCY STUDIES BY FLOW CYTOMETRY
CHALLENGES AND SOLUTIONS TO RECEPTOR OCCUPANCY STUDIES BY FLOW CYTOMETRY 4th RSC / DMDG / DMG New Perspectives in DMPK James Munday Science Lead I&I (Harrogate, UK) 21 st -22nd May 2018 Copyright 2018
More informationM&S in early development (to support FTiM)
Modelling and simulation support for design of First-in- Man studies: the MEL approach Hélène Karcher, Stacey Tannenbaum, Philip Lowe Modelling & Simulation, Novartis Pharma G EM-EFPI Workshop on the role
More informationPreclinical Development of Biologics: Case-by-case, so get off of my case!
Preclinical Development of Biologics: Case-by-case, so get off of my case! Northeast Chapter SOT David Jacobson-Kram, Ph.D., DABT Office of New Drugs Center for Drug Evaluation and Research FDA October
More informationAn Integrated Approach to PK/PD/IG/Safety for Biologics
An Integrated Approach to PK/PD/IG/Safety for Biologics Moderator: Sanela Bilic, PharmD, MBA Novartis Oncology, Clinical Pharmacology Speakers: Sebastian Spindledreher, PhD, DMPK-Bx, Novartis AG Jennifer
More informationADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW
ADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW Johannes Stanta PhD Scientific Manager, Bioanalysis EBF ADC Training day June 2017 Copyright 2017 Covance. All Rights Reserved ADC Bioanalytical PK Assays
More informationVELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS
VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS Dr Mikael Bjerg Caspersen Industrial Biotechnology Conference August 10 th 2015 INNOVATIVE TECHNOLOGY
More informationMatthias Grossmann, MD PhD Principal Consultant Early Phase 2013 PAREXEL International
Challenges in translating a candidate antibody to clinical development Matthias Grossmann, MD PhD Principal Consultant Early Phase 2013 PAREXEL International Agenda Early clinical development of therapeutic
More informationModelling and simulation to help define MABEL and Starting dose in FIH studies
Modelling and simulation to help define MABEL and Starting dose in FIH studies B Laurijssens, BEL Pharm Consulting. Steven W Martin, Pharmacometrics Group, Dept Clinical Pharmacology, Pfizer, Sandwich
More informationImmunogenicity Assay Strategies for Antibody-Drug Conjugates
Immunogenicity Assay Strategies for Antibody-Drug Conjugates 8th World ADC Conference, San Diego 20 Sep 2017 Seema Kumar, PhD Associate Scientific Director Global Early Development (GED) EMD Serono Research
More informationRevised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion
Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion Robin Thorpe & Meenu Wadhwa Revised Guideline: Differences from original
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationWhy Knowledge of Translational PK/PD at Sites of Action Are Important to Optimize Bispecific Antibody Development?
Why Knowledge of Translational PK/PD at Sites of Action Are Important to Optimize Bispecific Antibody Development? Weirong Wang, Ph.D. Biologics Clinical Pharmacology Why Knowledge of Translational PK/PD
More informationOvercoming drug & target interference in ADA and nabassays
Overcoming drug & target interference in ADA and nabassays Robert Nelson Ph.D. MRQA Head of Bioanalytical Laboratory, Novimmune SA 1 Presentation Outline Case Study 1 Drug & target interference in a clinical
More informationOptimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances
Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationInvestigations in Immune Suppression for Monoclonal Antibody Therapeutics
Investigations in Immune Suppression for Monoclonal Antibody Therapeutics Vibha Jawa Principal Scientist AAPS NBC Meeting, May 2016 Clinical Immunology, Medical Sciences, Amgen Background Therapeutic proteins
More informationJuvenile toxicity studies with biopharmaceuticals : considerations and current practices
Juvenile toxicity studies with biopharmaceuticals : considerations and current practices Shaun Maguire Toxicologist, Biologics Safety Assessment, MedImmune, Cambridge, UK maguires@medimmune.com AGAH Workshop
More informationUpdate on the new immunogenicity guideline in the EU
Update on the new immunogenicity guideline in the EU draft 2016 EBF, Lisbon 27 th September 2016 Venke Skibeli, Senior Scientist, PhD Norwegian Medicines Agency, Member of the CHMP - BMWP, EMA, London
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationImmunogenicity of biotherapeutics; an introduction
Immunogenicity of biotherapeutics; an introduction PKUK 6 th November 2014 Hishani Kirby PhD, UCB Contents Background The importance of understanding Anti drug antibodies (ADAs) The immune response Factors
More informationSUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007
European Medicines Agency SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007 COMMENTS FROM The Biotechnology
More informationImmunogenicity. How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit
Immunogenicity How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit Club Phase I, 22 March 2016 1 Outline Introduction to immunogenicity Analytical challenges for immunogenicity
More informationAn innovative approach for detecting NAb directed to antibodyderived therapeutics based on the bridging ADA assay
Nanobodies Innovative therapeutics An innovative approach for detecting NAb directed to antibodyderived therapeutics based on the bridging ADA assay Lieselot Bontinck, Scientist Outline Background Ablynx
More informationSubmission preparation what to watch out for
Submission preparation what to watch out for EBF 2017 Boris Gorovits AAPS BIOTEC section Pfizer June 2017 Analytes Commonly Assessed for ADC PK Unconjugated Drug analyte Total Antibody analyte Conjugated
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationH.P. Grimm (1), F. Crameri (1), H. Hinton (2), D. Türck (1), H. Silber Baumann (1), B. Ribba (1)
Intricate PK and PD for the novel immunocytokine CEA-IL2v and their pre-clinical to clinical translation H.P. Grimm (1), F. Crameri (1), H. Hinton (2), D. Türck (1), H. Silber Baumann (1), B. Ribba (1)
More informationImmunogenicity of Biological products
Immunogenicity of Biological products Pierre Cortez Sanofi-aventis Metabolism and Pharmacokinetic Department, Lyon / April 28, 2009 Agenda Introduction Immunogenicity monitoring Guidelines, white papers
More informationStrategies to Improve Drug Tolerance in Nab Assays
Strategies to Improve Drug Tolerance in Nab Assays Steven J Swanson, PhD Senior Vice President, Research ImmunoCellular Therapeutics Ltd steven.swanson@imuc.com AAPS National Biotech Conference June 2015
More informationChallenges in Developing a Neutralizing Antibody Assay for a Cyno Toxicology Study
Challenges in Developing a Neutralizing Antibody Assay for a Cyno Toxicology Study Robin Marsden, Sr. Mgr., Bioanalytical Sciences, La Jolla Pharmaceutical Co. Kristine de Dios, M.S., Scientist, Preclinical
More informationAndrew Nesbitt, PhD. Disclaimer 10/10/2014. Determining the Immunogenicity of Biologics: a Tricky Problem. Employee of UCB ן
Determining the Immunogenicity of Biologics: a Tricky Problem Andrew Nesbitt, PhD UCB Director Cimzia PST Disclaimer 2 Employee of UCB The theories expressed in this presentation are the views of the speaker
More informationVladimir Hanes, MD, USA
GaBI Educational Workshops 20 January 2015, Sheraton Maria Isabel Hotel & Towers, Mexico City, Mexico Vladimir Hanes, MD, USA Medical Director, Oncology Global Biosimilars Development, Amgen Inc GaBI Educational
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationFirst-in-human clinical trials Behind the scenes
First-in-human clinical trials Behind the scenes Dr Douglas Francis BVSc MVSc PhD, UK/European registered toxicologist Principal Regulatory Toxicologist Prior to review by Bellberry Ethics Committee Identify
More information06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND
Preclinical Support for Exploratory Phase I Clinical Trials Clive Joseph, DSRD Sandwich Overview Identify the most appropriate development paradigm - traditional vs alternative IND approach Confidence
More informationRisk-based testing for anti-drug neutralizing antibodies during development of biological therapeutics
Risk-based testing for anti-drug neutralizing antibodies during development of biological therapeutics April 18 th, 2016 AAPS National Biotechnology Conference, Boston, MA Shalini Gupta, PhD Amgen Inc.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 London, 23 July 2009 EMEA/CHMP/BMWP/301636/2008 4 5 6 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
More informationPK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis
More informationApplying Affimers. Dr Amanda Nicholl at Avacta Life Sciences. Improving Antibody PK Assay Development
Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting Applying Affimers With an increasing number of antibody-based therapeutics entering the clinic, the need for validated anti-idiotypic
More informationGuidance for Establishing Safety in First-in-Human Studies during Drug Development CONTENTS SUMMARY INTRODUCTION SCOPE
Guidance for Establishing Safety in First-in-Human Studies during Drug Development CONTENTS SUMMARY...1 1. INTRODUCTION...1 2. SCOPE...2 3. MAIN GUIDANCE TEXT...2 3.1 Risk Factors...2 3.1.1 Mechanism of
More information6 th EBF Open meeting, Barcelona November 21st, 2013
Validation of an immunoassay to selectively quantify the naked antibody of a new Sanofi Antibody Drug Conjugate: an additional tool for improvement of PK interpretation 6 th EBF Open meeting, Barcelona
More informationGuideline on similar medicinal products containing somatropin. Draft agreed by BMWP March Adopted by CHMP for release for consultation May 2005
28 June 2018 EMEA/CHMP/BMWP/94528/2005 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Annex to Guideline on similar biological medicinal products containing biotechnology-derived proteins
More informationImmunogenicity Assessment - Challenges and Strategies
Immunogenicity Assessment - Challenges and Strategies 17Nov2015 Manju Saxena, Ph.D. Scientific Director Intertek Pharmaceutical Services 1 Presentation Outline Introduction Immunogenicity Testing (ADA
More informationBiosimilars Scientific and Regulatory Considerations
Biosimilars Scientific and Regulatory Considerations Gustavo Grampp Regulatory Policy Director, Amgen Presented at Maryland Pharmacists Association meeting January 31, 2016 Program objectives 1. Review
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/94528/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE
More informationQuality attributes impacting immunogenicity of therapeutic proteins
www.pei.de Quality attributes impacting immunogenicity of therapeutic proteins Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins 9th March 2016 (EMA, Room 3A) Steffen
More informationNeutralising Assay Methodologies
Neutralising Assay Methodologies March 9 th, 2016 EMA workshop on immunogenicity assessment of biotechnology derived therapeutic proteins Shalini Gupta, PhD Amgen Inc. shalinig@amgen.com 1 Key Points About
More informationTarget-mediated Clearance and Immunogenicity two sides, one coin. Daren Austin, PhD Senior Director and Head Biopharm Clinical Pharmacology
Target-mediated Clearance and Immunogenicity two sides, one coin Daren Austin, PhD Senior Director and Head Biopharm Clinical Pharmacology Pharmacokinetic determinants of therapeutic proteins Pharmacokinetic
More informationPrecipitation and Acid (PandA) to Resolve the Drug and Target Interference Problems in Immunogenicity Assays
Precipitation and Acid (PandA) to Resolve the Drug and Target Interference Problems in Immunogenicity Assays Jad Zoghbi Senior Scientist Boston BCB, Sanofi, Framingham, MA Introduction Circulating therapeutic
More informationNDA Advisory Services Ltd
Declaration of Interest statement: Paul Chamberlain has received Consulting fees from different companies in respect of strategic and operational advice relating to biopharmaceutical development; he is
More informationADA-formation and its effect on Monoclonal Antibody PK
ADA-formation and its effect on Monoclonal Antibody PK María J. Garrido www.unav.edu/psp Agenda Defintion ADAs production Types of ADAs mabs and Immunogenicity ADME processes Technical assays PK models
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationEuropean Bioanalysis Forum
European Bioanalysis Forum Alternative Approaches for Assessment of Drug Neutralizing Activity of ADA Responses Presenter: Arjen Companjen (on behalf of EBF topic team 19) EIP meeting Lisbon 25 February
More informationGuideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating
1 2 3 26 July 2018 EMEA/CHMP/BMWP/31329/2005 Rev 1 Committee for Medicinal Product for Human Use (CHMP) 4 5 6 7 Guideline on similar biological medicinal products containing recombinant granulocyte-colony
More informationProteoGenix. Life Sciences Services and Products. From gene to biotherapeutics Target Validation to Lead optimisation
ProteoGenix Life Sciences Services and Products From gene to biotherapeutics Target Validation to Lead optimisation ProteoGenix Philippe FUNFROCK, founder and CEO French company located in Strasbourg,
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/32775/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE ON SIMILAR BIOLOGICAL
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation
More informationFDA Draft Guidance on Immunogenicity Testing
FDA Draft Guidance on Immunogenicity Testing Susan Kirshner, Ph.D. Associate Chief, Laboratory of Immunology Division of Therapeutic Proteins OBP/CDER/FDA EBF 2010 Guidance for Industry Assay Development
More informationTarget/drug interference considerations in immunogenicity assessment
Target/drug interference considerations in immunogenicity assessment Eric Wakshull, PhD Senior Scientist March 9, 2016 EMA Workshop on Immunogenicity Outline Page 2 Basic Immunogenicity screening assay
More informationMonoclonal Antibodies for Treatment and Prevention of HIV-1 CROI Charles Boucher Erasmus MC
Monoclonal Antibodies for Treatment and Prevention of HIV-1 CROI 2018 Charles Boucher Erasmus MC Introduction: Human monoclonal antibodies Monoclonal Antibodies: Are identical immunoglobulins made by clone
More informationPLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS
PLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS Louise Angell Lead Scientist 10th Biosimilars & Follow-On Biologics Congregation 9 th May 2017 Copyright @ 2017 Covance. All rights Reserved Overview
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationInterplay of Cells involved in Therapeutic Agent Immunogenicity. Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology
Interplay of Cells involved in Therapeutic Agent Immunogenicity Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology Disclosure The author works with Amicus on an immunogenicity project
More informationCurrent Experience in Immunogenicity Assessment of next Generation Biologics- Nanobodies
Current Experience in Immunogenicity Assessment of next Generation Biologics- Nanobodies European Immunogenicity Symposium Veerle Snoeck Nanobodies - Inspired by nature Ablynx NV Outline! Introduction!
More informationA regulatory update on the EU guideline on First-in-Human clinical trials
A regulatory update on the EU guideline on First-in-Human clinical trials Thomas Sudhop, BfArM, Bonn Thomas Sudhop A regulatory update on the EU guideline on First-in-Human clinical trials 17 May 2017
More informationBiosimilars China Guideline. Dr Dr Michel Mikhail
Biosimilars China Guideline Dr Dr Michel Mikhail 1 Contents Regulatory context of biologicals in China Decree 28 issued by SFDA October 2007 Proposed biosimilars guideline 10/29/14 Reference drugs to use
More informationComments and suggestions from reviewer
Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12
More informationDr. S. Harinarayana Rao
Dr. S. Harinarayana Rao Theatre, Indian Habitat Centre, New Delhi July 30 31, 2013 Introduction Classification ICH 6 guidelines Innovative methods RCGM and EMEA Challenges Conclusion What is a biopharmaceutical
More informationFebruary 28, Churchill Place Canary Wharf London E14 5EU United Kingdom
February 28, 2017 Submission of comments on 'Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products' (EMEA/CHMP/SWP/28367/07
More informationICH Topic S 6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Step 5
European Medicines Agency March 1998 CPMP/ICH/302/95 ICH Topic S 6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED
More informationJan Willem van der Laan
First-in-human studies: Recent experiences in Europe Jan Willem van der Laan Section Pharmacological-Toxicological and Biotechnology Assessment Medicines Evaluation Board, Utrecht First-in-human trials
More informationCase Studies on ultra-sensitive immunoanalytics based on Imperacer (Immuno-PCR) in clinical settings. Jan Detmers, Ph.D. (Chimera Biotec GmbH)
Case Studies on ultra-sensitive immunoanalytics based on Imperacer (Immuno-PCR) in clinical settings. Jan Detmers, Ph.D. (Chimera Biotec GmbH) Agenda 1.Overview Platforms 2.Immuno-PCR (Imperacer ) Technology
More informationClosed Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies October 2011 Dr Christian K Schneider, MD
Draft guideline on biosimilar monoclonal antibodies Closed Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies October 2011 Dr Christian K Schneider, MD CHMP Biosimilar
More informationStrategy for Selecting NAb Assay Format
Strategy for Selecting NAb Assay Format European Bioanalysis Forum 27Sept2016 Jim McNally, Ph.D. Associate Director, Global Early Development Head of Clinical Bioanalytics Merck KGaA AAPS Working Group
More informationChallenges for Flow Cytometry in Regulated Bioanalysis
Challenges for Flow Cytometry in Regulated Bioanalysis Minesh Patel Merck Millipore Discovery & Development Solutions. Oxford, UK. Overview Flow cytometry principles Current uses and regulatory environments
More informationXpress CF+ : A Cell-Free Platform for the Rapid Screening and Production of Homogeneous ADCs
Xpress CF+ : A Cell-Free Platform for the Rapid Screening and Production of Homogeneous ADCs Alexander R. Steiner, M.S. Director, Protein Biochemistry Tuesday Feb 3 rd, 215 Making novel drugs is Pammolli
More informationCase Study: A Phase-Driven Approach to the Development and Lifecycle Management of Potency Assays. Spring in New England!!!
Case Study: A Phase-Driven Approach to the Development and Lifecycle Management of Potency Assays CASSS Bioassays 2016: Scientific Approaches & Regulatory Strategies Session Potency Assays: Cell-based
More informationAssays for Immunogenicity: Are We There Yet?
Assays for Immunogenicity: Are We There Yet? Mark Wener, MD Department of Laboratory Medicine & Rheumatology Division Department of Medicine University of Washington Seattle, WA 98195 wener@uw.edu Goals:
More information3D Structure of Biologics in a Convenient Immunoassay Format
3D Structure of Biologics in a Convenient Immunoassay Format Xing Wang, Ph.D. Array Bridge Inc. 5/25/2017 1 Topics Covered Today Why New Technologies? Technology Development. Case Studies for Novel and
More informationAntibody-Drug Conjugate Bioanalytical Assay Development:
Antibody-Drug Conjugate Bioanalytical Assay Development: Immunogenicity Challenges November 16, 2016 Presented by Corinna Fiorotti, Ph.D. Presentation Overview ADC Overview ADC Assays ADC Immunogenicity
More informationControl Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design!
Control Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design! Marjorie Shapiro Office of Biotechnology Products/FDA WCBP 2017 January 25, 2017 Disclaimer The views presented
More informationScientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationIdentification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy
Identification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy Ziping Wei, Ph.D. Analytical Biochemistry MedImmune January 25, 2010 Outline Why do we need to identify
More informationMethods to Determine the Binding of Bevacizumab to Fc receptors
DATASHEET Methods to Determine the Binding of Bevacizumab to Fc receptors BACKGROUND Bevacizumab (Avastin ) is a humanized recombinant monoclonal antibody that inhibits angiogenesis by binding to the vascular
More informationHigh affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD)
High affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD) Devang Shah Senior Principal Investigator Metabolism and Pharmacokinetics, Pharmaceutical
More informationChallenges in Bioassay Development for ADCs and Their Utility for Measuring In-vitro Activity of Conjugate Variants
Challenges in Bioassay Development for ADCs and Their Utility for Measuring In-vitro Activity of Conjugate Variants Sonia Connaughton, Ph.D. Senior Scientist, Bioanalytical Science Bioassays 214: Scientific
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationDDI Assessment for Therapeutic Proteins and ADCs
DDI Assessment for Therapeutic Proteins and ADCs Elimika Pfuma Fletcher, PharmD, PhD Policy Lead Guidance and Policy Team Office of Clinical Pharmacology CDER/FDA 06/21/2017 DDI- 2017 International Conference
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationGuideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics
Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food
More informationIMPROVE SPEED AND ACCURACY OF MONOCLONAL ANTIBODY BIOANALYSIS USING NANOTECHNOLOGY AND LCMS
IMPROVE SPEED AND ACCURACY OF MONOCLONAL ANTIBODY BIOANALYSIS USING NANOTECHNOLOGY AND LCMS As scientists gain an advanced understanding of diseases at the molecular level, the biopharmaceutical industry
More informationInformative study designs Where modelling and simulation based design features make a trial more informative than a comparable standard design
Pharmacometrics, CD&A Informative study designs Where modelling and simulation based design features make a trial more informative than a comparable standard design Martin Fink, Mark Milton & Phil Lowe
More information1994 Gerhard Levy mab target-mediated drug disposition TM- DD TMDD TMDD TMDD TMDD PK / PK / PD PK
481 CN 34-1206 /R ISSN 1009-2501 http / /www. cjcpt. com 2018 May 23 5 481-487 1 2 1 1 1 1 100022 2 9016 R969 A 1009-2501 2018 05-0481-07 doi 10. 12092 /j. issn. 1009-2501. 2018. 05. 001 1994 Gerhard Levy
More informationDesign and Validation of a Non Cell-based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic
Design and Validation of a Non Cell-based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic Shalini Gupta Associate Director Amgen, Thousand Oaks, CA shalinig@amgen.com
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 16 June 2005 EMEA/CHMP/94526/2005 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) ANNEX GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT GUIDANCE This guidance document is being distributed for comment
More information